{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:06:52Z","timestamp":1794258412624,"version":"4.9.0"},"reference-count":184,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"AstraZeneca Canada Inc; Janssen Canada"},{"name":"Daiichi Sankyo Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mutations of the gene EGFR are frequent oncogenic drivers in non\u2013small cell lung cancer (NSCLC). Third-generation EGFR tyrosine kinase inhibitors, which target common EGFR mutations and the acquired T790M resistance mutation, offer improved inhibitory potency and selectivity. Our review critically assessed the evolving role of these agents for management of NSCLC harboring common EGFR mutations. Multiple global phase 3 trials have evaluated third-generation EGFR tyrosine kinase inhibitors in patients with NSCLC and common EGFR mutations. The addition of osimertinib to curative-intent strategies have demonstrated improvements in disease-free survival and overall survival as adjuvant therapy in patients with resected stage IB-IIIA tumors, major pathological responses compared with chemotherapy when used as neoadjuvant therapy, and progression-free survival compared with placebo when used as consolidation therapy in patients with unresectable stage III disease. Furthermore, third-generation EGFR tyrosine kinase inhibitor monotherapy improved progression-free survival compared with first-generation EGFR tyrosine kinase inhibitors in the first-line treatment of advanced disease. Intensification strategies, such as the addition of chemotherapy or a bispecific antibody, have further enhanced progression-free survival and overall survival outcomes. Several new therapeutic options are emerging for patients previously treated with third-generation EGFR tyrosine kinase inhibitors. Currently, subsequent treatment recommendations include chemotherapy or datopotamab deruxtecan following progression on a third-generation EGFR tyrosine kinase inhibitor combination and amivantamab plus platinum-based chemotherapy following progression on monotherapy. The treatment landscape for NSCLC with common EGFR mutations is rapidly evolving, and third-generation EGFR tyrosine kinase inhibitors play an integral role in both the curative-intent and palliative settings.<\/jats:p>","DOI":"10.1093\/jnci\/djag008","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:37:47Z","timestamp":1767875867000},"page":"789-810","source":"Crossref","is-referenced-by-count":6,"title":["Targeting common\n                    <i>EGFR<\/i>\n                    mutations in non\u2013small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2865-659X","authenticated-orcid":false,"given":"Barbara","family":"Melosky","sequence":"first","affiliation":[{"name":"British Columbia Cancer Agency\u2014Vancouver Centre, University of British Columbia , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-4704","authenticated-orcid":false,"given":"Rosalyn A","family":"Juergens","sequence":"additional","affiliation":[{"name":"Juravinski Cancer Centre, McMaster University , Hamilton, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-3126","authenticated-orcid":false,"given":"Quincy S C","family":"Chu","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, University of Alberta , Edmonton, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9680-7073","authenticated-orcid":false,"given":"Parneet","family":"Cheema","sequence":"additional","affiliation":[{"name":"William Osler Health System, Department of Medicine, University of Toronto , Brampton, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3847-0289","authenticated-orcid":false,"given":"Stephanie","family":"Snow","sequence":"additional","affiliation":[{"name":"QEII Health Sciences Centre, Department of Medicine, Dalhousie University , Halifax, NS,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-4602","authenticated-orcid":false,"given":"Natasha B","family":"Leighl","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-4362","authenticated-orcid":false,"given":"Normand","family":"Blais","sequence":"additional","affiliation":[{"name":"Centre hospitalier de l\u2018Universit\u00e9 de Montr\u00e9al, Department of Medicine, University of Montreal , Montreal, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana N","family":"Ionescu","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Agency\u2014Vancouver Centre, University of British Columbia , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-3726","authenticated-orcid":false,"given":"Deanna","family":"McLeod","sequence":"additional","affiliation":[{"name":"Kaleidoscope Strategic Inc , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9160-5405","authenticated-orcid":false,"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-9767","authenticated-orcid":false,"given":"Paul","family":"Wheatley-Price","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa , Ottawa, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-7296","authenticated-orcid":false,"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2026050811444704800_djag008-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026050811444704800_djag008-B2","first-page":"1367","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B3","first-page":"1191","article-title":"Lung cancer biomarkers: present status and future developments","volume":"137","author":"Cagle","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"2026050811444704800_djag008-B4","first-page":"2096","article-title":"Preoperative evaluation of patients undergoing lung resection surgery","volume":"123","author":"Datta","year":"2003","journal-title":"Chest"},{"key":"2026050811444704800_djag008-B5","doi-asserted-by":"publisher","first-page":"vii196","DOI":"10.1093\/annonc\/mdq376","article-title":"Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?","volume":"21(suppl 7)","author":"Le Chevalier","year":"2010","journal-title":"Ann Oncol."},{"key":"2026050811444704800_djag008-B6","first-page":"S24","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28(suppl 1)","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"2026050811444704800_djag008-B7","first-page":"973","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-a systematic review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B8","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"2026050811444704800_djag008-B9","first-page":"306","article-title":"Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review","volume":"4","author":"Chintala","year":"2010","journal-title":"Mol Oncol"},{"key":"2026050811444704800_djag008-B10","first-page":"169","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2026050811444704800_djag008-B11","first-page":"935","article-title":"Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review","volume":"11","author":"Passiglia","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"2026050811444704800_djag008-B12","first-page":"1331","article-title":"Uncommon and rare EGFR mutations in non-small cell lung cancer patients with a focus on Exon 20 insertions and the Phase 3 PAPILLON trial: the state of the art","volume":"16","author":"Fabrizio","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026050811444704800_djag008-B13","first-page":"101064","article-title":"Current management of uncommon EGFR mutations in non-small cell lung cancer","volume":"49","author":"Trinh","year":"2024","journal-title":"Curr Probl Cancer"},{"key":"2026050811444704800_djag008-B14","first-page":"8878","article-title":"Overview on therapeutic options in uncommon EGFR mutant Non-Small Cell Lung Cancer (NSCLC): new lights for an unmet medical need","volume":"24","author":"Pretelli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026050811444704800_djag008-B15","first-page":"1227","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann Oncol"},{"key":"2026050811444704800_djag008-B16","first-page":"e1","article-title":"Therapy for Stage IV non\u2013small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B17","first-page":"2425","article-title":"Clinical and molecular features of Epidermal Growth Factor Receptor (EGFR) mutation positive Non-Small-Cell Lung Cancer (NSCLC) patients treated with Tyrosine Kinase Inhibitors (TKIs): predictive and prognostic role of co-mutations","volume":"13","author":"Bironzo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026050811444704800_djag008-B18","first-page":"303","article-title":"FDA drug approval summary: gefitinib (ZD1839)(Iressa\u00ae) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"2026050811444704800_djag008-B19","first-page":"1040","article-title":"Therapy for stage IV non\u2013small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B20","first-page":"68","article-title":"Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma","volume":"11","author":"Wang","year":"2016","journal-title":"Open Med (Wars)"},{"key":"2026050811444704800_djag008-B21","first-page":"113","article-title":"Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)","volume":"137","author":"Gelatti","year":"2019","journal-title":"Lung Cancer"},{"key":"2026050811444704800_djag008-B22","first-page":"3867","article-title":"Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer","volume":"10","author":"Zhang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2026050811444704800_djag008-B23","first-page":"257","article-title":"Osimertinib","volume":"211","author":"Malapelle","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"2026050811444704800_djag008-B24","first-page":"585","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B25","first-page":"1711","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B26","first-page":"4208","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B27","first-page":"113","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B28","first-page":"3162","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B29","first-page":"88","article-title":"Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile","volume":"13","author":"S\u00f8rensen","year":"2024","journal-title":"Chin Clin Oncol"},{"key":"2026050811444704800_djag008-B30","first-page":"1019","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026050811444704800_djag008-B31","first-page":"677","article-title":"Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial","volume":"13","author":"Shi","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026050811444704800_djag008-B32","first-page":"327","article-title":"Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study","volume":"13","author":"Shi","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026050811444704800_djag008-B33","first-page":"S11","article-title":"OA02.04 A phase III study of Rilertinib versus Gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR-mutated NSCLC","volume":"19","author":"Zhou","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B34","first-page":"100513","article-title":"First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: the phase 3 EVEREST trial","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"2026050811444704800_djag008-B35","first-page":"173","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026050811444704800_djag008-B36","first-page":"1935","article-title":"Osimertinib with or without Chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B37","first-page":"1486","article-title":"Amivantamab plus Lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B38","first-page":"206","article-title":"Unveiling the synergistic potential: bispecific antibodies in conjunction with chemotherapy for advanced non-small-cell lung cancer treatment","volume":"32","author":"Khan","year":"2025","journal-title":"Curr Oncol"},{"key":"2026050811444704800_djag008-B39","first-page":"348","article-title":"Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer","volume":"22","author":"Wen","year":"2025","journal-title":"Cancer Biol Med"},{"key":"2026050811444704800_djag008-B40","first-page":"89","article-title":"Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2026050811444704800_djag008-B41","first-page":"286","article-title":"Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey","volume":"8","author":"Gregg","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2026050811444704800_djag008-B42","first-page":"339","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"2026050811444704800_djag008-B43","first-page":"1491","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"2026050811444704800_djag008-B44","first-page":"103996","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer","volume":"9","author":"Lee","year":"2024","journal-title":"ESMO Open"},{"key":"2026050811444704800_djag008-B45","first-page":"989","article-title":"Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a national consensus of the Spanish society of pathology and the Spanish society of medical oncology","volume":"22","author":"Garrido","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2026050811444704800_djag008-B46","first-page":"1445826","article-title":"Biomarker testing in lung cancer: from bench to bedside","volume":"18","author":"Batra","year":"2024","journal-title":"Oncol Rev"},{"key":"2026050811444704800_djag008-B47","first-page":"1373","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B48","first-page":"610","article-title":"Non\u2013small cell lung cancer: recommendations for biomarker testing and treatment","volume":"19","author":"Aisner","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2026050811444704800_djag008-B49","first-page":"100838","article-title":"Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries","volume":"38","author":"de Jager","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026050811444704800_djag008-B50","first-page":"4981","article-title":"Consensus recommendations to optimize testing for new targetable alterations in non-small cell lung cancer","volume":"29","author":"Ionescu","year":"2022","journal-title":"Curr Oncol"},{"key":"2026050811444704800_djag008-B51","first-page":"2219","article-title":"Shifting from Immunohistochemistry to screen for ALK rearrangements: real-world experience in a large single-center cohort of patients with non-small-cell lung cancer","volume":"16","author":"Ili\u00e9","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026050811444704800_djag008-B52","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2026050811444704800_djag008-B53","first-page":"455","article-title":"Liquid biopsy in diagnosis and monitoring of treatment efficacy in patients with small cell lung cancer","volume":"52","author":"Galant","year":"2025","journal-title":"Mol Biol Rep"},{"key":"2026050811444704800_djag008-B54","first-page":"1116","article-title":"Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study","volume":"35","author":"Lu","year":"2024","journal-title":"Ann Oncol"},{"key":"2026050811444704800_djag008-B55","first-page":"2875","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clinl Oncol"},{"key":"2026050811444704800_djag008-B56","first-page":"1830","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non\u2013small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B57","first-page":"137","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B58","first-page":"S112","article-title":"OA06. 03 Patient-reported outcomes from ADAURA: osimertinib as adjuvant therapy in patients with resected EGFR mutated (EGFRm) NSCLC","volume":"16","author":"Majem","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B59","first-page":"CT126","article-title":"Abstract CT126: Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: a randomized, double-blind, placebo-controlled, phase 3 trial (ARTS)","volume":"85","author":"Cheng","year":"2025","journal-title":"Cancer Res"},{"key":"2026050811444704800_djag008-B60","first-page":"S123","article-title":"LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): updated overall survival (OS) analysis from the LAURA study","volume":"20","author":"Ramalingam","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B61","first-page":"S6","article-title":"PL04.13 Aumolertinib maintenance after Chemoradiotherapy in stage III non-small-cell lung cancer: interim results of the phase III study (POLESTAR)","volume":"19","author":"Yu","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B62","first-page":"8048","article-title":"Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable EGFR-mutated stage III NSCLC: final analysis of the phase III advance trial and real-world data","volume":"43","author":"Bi","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B63","author":"U.S. Food and Drug Administration"},{"key":"2026050811444704800_djag008-B64","author":"U.S. Food and Drug Administration"},{"key":"2026050811444704800_djag008-B65","article-title":"TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection","volume":"2","author":"Soo","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"2026050811444704800_djag008-B66","first-page":"2847","article-title":"Neoadjuvant osimertinib: a step ahead or just a step?","volume":"43","author":"Ramalingam","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B67","first-page":"59","article-title":"Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: a review","volume":"177","author":"Blakely","year":"2023","journal-title":"Lung Cancer"},{"key":"2026050811444704800_djag008-B68","first-page":"629","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B69","first-page":"1330468","article-title":"Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report","volume":"13","author":"Mirza","year":"2023","journal-title":"Front Oncol"},{"key":"2026050811444704800_djag008-B70","first-page":"459","article-title":"Optimizing osimertinib for NSCLC: targeting resistance and exploring combination therapeutics","volume":"17","author":"Liao","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050811444704800_djag008-B71","first-page":"2654","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026050811444704800_djag008-B72","first-page":"90","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)","volume":"59","author":"He","year":"2021","journal-title":"Int J Oncol"},{"key":"2026050811444704800_djag008-B73","first-page":"908","article-title":"Histological transformation after acquired resistance to the Third-generation EGFR-TKI in patients with advanced EGFR-mutant lung adenocarcinoma","volume":"58","author":"Lee","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"2026050811444704800_djag008-B74","first-page":"101260","article-title":"Consensus on the lung cancer management after third-generation EGFR-TKI resistance","volume":"53","author":"Zhou","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"2026050811444704800_djag008-B75","first-page":"839","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"2026050811444704800_djag008-B76","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2026050811444704800_djag008-B77","first-page":"5448","article-title":"Systemic therapy for small-cell lung cancer: ASCO-Ontario health (Cancer Care Ontario) guideline","volume":"41","author":"Khurshid","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B78","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3322\/caac.70024","article-title":"Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026050811444704800_djag008-B79","first-page":"41","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B80","first-page":"108417","article-title":"Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study","volume":"202","author":"Garassino","year":"2025","journal-title":"Lung Cancer"},{"key":"2026050811444704800_djag008-B81","author":"U.S. Food and Drug Administration"},{"key":"2026050811444704800_djag008-B82","author":"AstraZeneca"},{"key":"2026050811444704800_djag008-B83","first-page":"2317","article-title":"Randomized phase III study of EGFR tyrosine kinase inhibitor and intercalated platinum-doublet chemotherapy for non-small cell lung cancer harboring EGFR mutation","volume":"31","author":"Kanda","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026050811444704800_djag008-B84","first-page":"124","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B85","first-page":"115","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B86","first-page":"3587","article-title":"Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"40","author":"Miyauchi","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B87","first-page":"27","volume-title":"N Engl J Med","author":"J\u00e4nne","year":"2026"},{"key":"2026050811444704800_djag008-B88","first-page":"S6","article-title":"4O: Amivantamab plus Lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study","volume":"20","author":"Yang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B89","first-page":"1681","article-title":"Overall survival with Amivantamab-Lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B90","first-page":"S14","article-title":"10MO: preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with Amivantamab plus Lazertinib: Early success of the COCOON trial","volume":"20","author":"Girard","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B91","first-page":"1655","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026050811444704800_djag008-B92","first-page":"1086","article-title":"Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the Beverly multicenter randomized phase 3 trial","volume":"17","author":"Piccirillo","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B93","first-page":"625","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026050811444704800_djag008-B94","first-page":"1533","article-title":"Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706)","volume":"16","author":"Zhao","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B95","first-page":"S1374","article-title":"2O IMpower010: biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC","volume":"32","author":"Zhou","year":"2021","journal-title":"Ann Oncol."},{"key":"2026050811444704800_djag008-B96","first-page":"215","article-title":"Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026050811444704800_djag008-B97","first-page":"809","article-title":"Preventing infusion-related reactions with intravenous Amivantamab-results from SKIPPirr, a phase 2 study: a brief report","volume":"20","author":"Spira","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B98","first-page":"3593","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with Lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B99","author":"Johnson & Johnson"},{"key":"2026050811444704800_djag008-B100","author":"U.S. Food and Drug Administration"},{"key":"2026050811444704800_djag008-B101","first-page":"S102","article-title":"MA12.04 FLAURA2: impact of tumor burden on outcomes of 1L osimertinib +\/- chemotherapy in patients with EGFR-mutated advanced NSCLC","volume":"19","author":"Valdiviezo","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B102","author":"U.S. Food and Drug Administration"},{"key":"2026050811444704800_djag008-B103","author":"AstraZeneca"},{"key":"2026050811444704800_djag008-B104","author":"U.S. Food and Drug Administration"},{"key":"2026050811444704800_djag008-B105","author":"Johnson & Johnson"},{"key":"2026050811444704800_djag008-B106","first-page":"40","article-title":"Geriatric oncology research in the cooperative groups: a report of a SIOG special meeting","volume":"1","author":"Hurria","year":"2010","journal-title":"J Geriatr Oncol"},{"key":"2026050811444704800_djag008-B107","first-page":"1854","article-title":"Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial","volume":"38","author":"Nakashima","year":"2020","journal-title":"Invest New Drugs"},{"key":"2026050811444704800_djag008-B108","first-page":"665","article-title":"A prospective phase II trial of first-line osimertinib for patients with EGFR mutation-positive NSCLC and poor performance status (OPEN\/TORG2040)","volume":"20","author":"Fukui","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B109","first-page":"102583","article-title":"4O First-line (1L) osimertinib (osi) +\/- platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes","volume":"9","author":"Valdiviezo","year":"2024","journal-title":"ESMO Open"},{"key":"2026050811444704800_djag008-B110","first-page":"1601","article-title":"Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy","volume":"10","author":"Al-Halabi","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B111","first-page":"1233","article-title":"Treatment approaches for oligoprogressive non-small cell lung cancer: a review of ablative radiotherapy","volume":"17","author":"Gombrich","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050811444704800_djag008-B112","first-page":"742","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"2026050811444704800_djag008-B113","first-page":"412","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase III trial","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B114","first-page":"103435","article-title":"Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"87","author":"Sampath","year":"2025","journal-title":"eClinicalMedicine"},{"key":"2026050811444704800_djag008-B115","first-page":"975","article-title":"Phase 2 trial of consolidative stereotactic body radiation therapy in patients with metastatic oncogene-driven non-small cell lung carcinoma treated with tyrosine kinase inhibitors","volume":"121","author":"Keane","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026050811444704800_djag008-B116","first-page":"100559","article-title":"Pneumonitis in patients receiving thoracic radiotherapy and osimertinib: a multi-institutional study","volume":"4","author":"Banla","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"2026050811444704800_djag008-B117","first-page":"4287","article-title":"Role of radiotherapy in advanced oncogenic-driven oligometastatic non-small cell lung cancer patients: a narrative review","volume":"17","author":"Zhang","year":"2025","journal-title":"J Thora Dis"},{"key":"2026050811444704800_djag008-B118","first-page":"30650","article-title":"Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"2026050811444704800_djag008-B119","first-page":"2202","article-title":"Current status of multimodal therapy for oligometastatic disease, induced oligometastatic disease, and oligo-progressive disease in EGFR-mutated non-small-cell lung cancer","volume":"17","author":"Miyawaki","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050811444704800_djag008-B120","first-page":"3409","article-title":"The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review","volume":"10","author":"Berzenji","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"2026050811444704800_djag008-B121","first-page":"17","article-title":"The current consensus on salvage surgery after targeted therapy for advanced EGFR-mutant non-small cell lung cancer","volume":"59","author":"Liu","year":"2026","journal-title":"J Chest Surg"},{"key":"2026050811444704800_djag008-B122","first-page":"5820","article-title":"Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases","volume":"14","author":"Kahraman","year":"2024","journal-title":"Sci Rep"},{"key":"2026050811444704800_djag008-B123","first-page":"129","article-title":"Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors","volume":"33","author":"Kashima","year":"2016","journal-title":"Med Oncol"},{"key":"2026050811444704800_djag008-B124","first-page":"967946","article-title":"Impact of epilepsy and its treatment on brain metastasis from solid tumors: a retrospective study","volume":"13","author":"Maschio","year":"2022","journal-title":"Front Neurol"},{"key":"2026050811444704800_djag008-B125","first-page":"967","article-title":"Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial","volume":"23","author":"Yang","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026050811444704800_djag008-B126","first-page":"110334","article-title":"Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: results & reflections from the prematurely closed phase III HYBRID trial","volume":"197","author":"Zeng","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026050811444704800_djag008-B127","first-page":"JCO2018783118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B128","first-page":"1756","article-title":"Central nervous system outcomes of lazertinib versus gefitinib in EGFR-mutated advanced NSCLC: a LASER301 subset analysis","volume":"18","author":"Soo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B129","first-page":"OA02.05","article-title":"OA02.05 lazertinib vs osimertinib in 1L EGFR-mutant advanced NSCLC: a randomized, double-blind, exploratory analysis from MARIPOSA","volume":"19","author":"Lee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B130","first-page":"905","article-title":"Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Resp Med"},{"key":"2026050811444704800_djag008-B131","first-page":"1005","article-title":"Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)","volume":"44","author":"Lu","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"2026050811444704800_djag008-B132","first-page":"e2255050","article-title":"Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non-small cell lung cancer in patients with brain metastases: the GAP BRAIN open-label, randomized, multicenter, phase 3 study","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026050811444704800_djag008-B133","first-page":"22901","article-title":"First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"2026050811444704800_djag008-B134","first-page":"S10","article-title":"OA02.03 Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: longer follow-up of the MARIPOSA study","volume":"19","author":"Gadgeel","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B135","first-page":"808","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B136","first-page":"377","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer"},{"key":"2026050811444704800_djag008-B137","first-page":"805","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann Oncol"},{"key":"2026050811444704800_djag008-B138","first-page":"3752","article-title":"Circulating tumor DNA kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)","volume":"28","author":"Mack","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026050811444704800_djag008-B139","first-page":"100","article-title":"Single cell RNA sequencing identifies IGFBP5 and QKI as ciliated epithelial cell genes associated with severe COPD","volume":"22","author":"Li","year":"2021","journal-title":"Respir Res"},{"key":"2026050811444704800_djag008-B140","first-page":"S1563","article-title":"LBA12 tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study","volume":"33(suppl 9)","author":"Ahn","year":"2022","journal-title":"Ann Oncol."},{"key":"2026050811444704800_djag008-B141","first-page":"3340","article-title":"Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; exploratory analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026050811444704800_djag008-B142","first-page":"CT017","article-title":"Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed","volume":"84","author":"J\u00e4nne","year":"2024","journal-title":"Cancer Res"},{"key":"2026050811444704800_djag008-B143","first-page":"S101","article-title":"MA12.03 FLAURA2: resistance, and impact of baseline TP53 alterations in patients treated with 1L osimertinib +\/- platinum-pemetrexed","volume":"19","author":"Yang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B144","author":"Wang","year":"2025"},{"key":"2026050811444704800_djag008-B145","first-page":"107248","article-title":"Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI\u2019s: Exploration of efficacy of unselected treatment in a multicenter cohort study","volume":"181","author":"Steendam","year":"2023","journal-title":"Lung Cancer"},{"key":"2026050811444704800_djag008-B146","first-page":"100007","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep Med"},{"key":"2026050811444704800_djag008-B147","doi-asserted-by":"publisher","first-page":"105807","DOI":"10.1016\/j.esmoop.2025.105807:105807","article-title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","volume":"10","author":"Peled","year":"2025","journal-title":"ESMO Open"},{"key":"2026050811444704800_djag008-B148","first-page":"77","article-title":"Amivantamab plus chemotherapy with and without Lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"2026050811444704800_djag008-B149","first-page":"S1244","article-title":"LBA54 amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: second interim overall survival from MARIPOSA-2","volume":"35(suppl 2)","author":"Popat","year":"2024","journal-title":"Ann Oncol."},{"key":"2026050811444704800_djag008-B150","article-title":"FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations","author":"U.S. Food and Drug Administration"},{"key":"2026050811444704800_djag008-B151","first-page":"651","article-title":"Amivantamab plus Lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 Cohort A","volume":"20","author":"Besse","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B152","first-page":"S4","article-title":"2O: SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and\/or amplification (Amp) following progressive disease (PD) on osi","volume":"20","author":"Ahn","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B153","first-page":"989","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026050811444704800_djag008-B154","first-page":"LBA8505","article-title":"Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): results from a randomized phase 3 SACHI study","volume":"43(17 suppl","author":"Lu","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B155","first-page":"1252","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor\u2013mutated metastatic non\u2013small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B156","first-page":"LBA9000","article-title":"Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study","volume":"41","author":"Yang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B157","first-page":"2288","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B158","first-page":"1241","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-rearranged or translocated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B159","first-page":"1167","article-title":"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026050811444704800_djag008-B160","first-page":"S64","article-title":"OA09.06 IMpower151: phase III study of Atezolizumab + Bevacizumab + Chemotherapy in 1L metastatic nonsquamous NSCLC","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B161","author":"Goldman","year":"2025"},{"key":"2026050811444704800_djag008-B162","author":"Summit Therapeutics"},{"key":"2026050811444704800_djag008-B163","first-page":"561","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"2026050811444704800_djag008-B164","author":"Ramalingam","year":"2025"},{"key":"2026050811444704800_djag008-B165","first-page":"5363","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B166","first-page":"8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B167","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N Engl J Med"},{"key":"2026050811444704800_djag008-B168","first-page":"S2","article-title":"1O: osimertinib (osi)+ datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD","volume":"20","author":"Le","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B169","first-page":"358","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"2026050811444704800_djag008-B170","first-page":"e45","article-title":"Therapy for stage IV non\u2013small cell lung cancer without driver alterations: ASCO living guideline, version 2025.1","volume":"43","author":"Owen","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B171","first-page":"e085680","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"389","author":"Fang","year":"2025","journal-title":"BMJ."},{"key":"2026050811444704800_djag008-B172","first-page":"8507","article-title":"Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): results from the randomized OptiTROP-Lung03 study","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B173","first-page":"1669","article-title":"A pooled analysis of Datopotamab Deruxtecan in patients with EGFR-mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026050811444704800_djag008-B174","author":"U.S. Food and Drug Administration"},{"key":"2026050811444704800_djag008-B175","first-page":"725","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"2026050811444704800_djag008-B176","first-page":"3924","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026050811444704800_djag008-B177","first-page":"466","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"key":"2026050811444704800_djag008-B178","first-page":"117178","article-title":"From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer","volume":"284","author":"Ahmad","year":"2025","journal-title":"Eur J Med Chem"},{"key":"2026050811444704800_djag008-B179","first-page":"2481392","article-title":"Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future","volume":"40","author":"Zhang","year":"2025","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2026050811444704800_djag008-B180","first-page":"18825","article-title":"Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review","volume":"13","author":"Mansour","year":"2023","journal-title":"RSC Adv"},{"key":"2026050811444704800_djag008-B181","first-page":"102824","article-title":"Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development","volume":"130","author":"Corvaja","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2026050811444704800_djag008-B182","first-page":"e2","article-title":"Therapy for stage IV non\u2013small cell lung cancer with driver alterations: ASCO living guideline, version 2024.3","volume":"43","author":"Owen","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050811444704800_djag008-B183","author":"AstraZeneca"},{"key":"2026050811444704800_djag008-B184","author":"AstraZeneca"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag008\/66327166\/djag008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/5\/789\/66327166\/djag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/5\/789\/66327166\/djag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:44:54Z","timestamp":1778255094000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/5\/789\/8418392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":184,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag008","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,9]]}}}